Stem Cell News

BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.

As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.

Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.

CPD-017 by Kataoka Corporation to Streamline iPSC Processing for the US Market

October 5, 2022 By Cade Hildreth, Founder & President Leave a Comment

Los Angeles, California, October 5, 2022 – Kataoka Corporation (Kyoto, Japan) and Kataoka-SS America Corporation (Carson, CA) have developed the CPD-017, a cell processing platform that uses cutting edge laser and AI technology to purify adherent iPSC cultures. [Read more…]

CRISPR Therapeutics Announces FDA RMAT Designation Granted to CTX130™ for Treatment of Cutaneous T-Cell Lymphomas

October 2, 2022 By Cade Hildreth, Founder & President Leave a Comment

ZUG, Switzerland and BOSTON, Sept. 28, 2022 – CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX130™, the Company’s wholly-owned allogeneic CAR T cell therapy targeting CD70, for the treatment of Mycosis Fungoides and Sézary Syndrome (MF/SS). [Read more…]

Defence Therapeutics Reports Reprogrammed MSC Vaccine Cures 80% of Animals with Lymphoma Cancer

September 21, 2022 By Cade Hildreth, Founder & President Leave a Comment

Breakthrough Results with Accum(TM) A1-Reprogrammed MSC, Mesenchymal Stem Cells, in a Novel Vaccine Cured 80% of Animals with Pre-Established Lymphoma

Vancouver, British Columbia, September 21, 2022 – Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report that Defence’s novel vaccine candidate triggers a potent anti-tumoral response capable of curing animals with pre-established lymphoma. [Read more…]

FUJIFILM Cellular Dynamics Announces Dr. Ilyas Singeç as Chief Scientific Officer

September 20, 2022 By Cade Hildreth, Founder & President Leave a Comment

September 15, 2022, MADISON, Wisconsin – FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSCs), today announces the appointment of Ilyas Singeç, M.D., as chief scientific officer effective September 12. In this newly created strategic role, Dr. Singeç will define the Company’s future iPSC technological pipeline. In his role as part of the Company’s executive leadership team, he will also help drive business strategy with the goal of transforming scientific research and healthcare by using iPSC technologies. [Read more…]

StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy

September 19, 2022 By BioInformant Team Leave a Comment

August 29, 2022, BALDWIN PARK, CA, — Southern California cord blood regenerative therapeutics company StemCyte is pleased to announce it has received approval from the U.S. Food and Drug Administration (FDA) for their Phase II clinical trial for Post-COVID Syndrome (or PCS) using umbilical cord blood stem cell therapy. PCS is also referred to as Long COVID and is characterized by lingering health effects or symptoms that are not explained by tests, which could last years. StemCyte aims to treat PCS by infusing umbilical cord blood that is capable of anti-inflammation and tissue repair. [Read more…]